EOLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evolus Inc (EOLS) is not a strong buy for a beginner, long-term investor at this moment. The stock lacks positive momentum, has weak technical indicators, and faces insider selling pressure. While the company has shown revenue growth, its profitability metrics have significantly declined. Additionally, there are no strong catalysts or favorable trading signals to justify immediate investment.
The MACD is negative and expanding downward (-0.00135), RSI is neutral at 42.587, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 4.768), with resistance levels at R1: 5.539 and R2: 5.778. Overall, the technical indicators suggest a lack of bullish momentum.
Revenue increased by 14.38% YoY in Q4 2025, and gross margin improved slightly to 63.64%.
Net income dropped significantly (-101.91% YoY), EPS fell to 0 (-100% YoY), and insider selling has surged by 683.57% over the last month. Analysts have lowered price targets recently, citing challenges in the aesthetic injectables market.
In Q4 2025, revenue showed growth (14.38% YoY), but net income and EPS deteriorated significantly (-101.91% and -100% YoY, respectively). Gross margin improved slightly to 63.64%, but profitability remains a concern.
Analysts have lowered price targets recently (Mizuho: $15 from $19, BTIG: $13 from $18) while maintaining positive ratings (Outperform/Buy). However, the updates reflect challenges in the market and revised long-term guidance.
